Search results (1331)
« Back to PublicationsA phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
Blagden SP., (2016), Annals of Oncology
Loss of LARP4B, an early event in the tumorigenesis of brain cancer?
Blagden S. et al, (2016), TRANSLATIONAL CANCER RESEARCH, 5, S1196 - S1199
Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP.
Lu M. et al, (2016), Cancer cell, 30, 822 - 823
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
Gupta A. et al, (2016), British Journal of Cancer
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Parkes EE. et al, (2016), Journal of the National Cancer Institute, 109, djw199 - djw199
Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
Harrison CN. et al, (2016), Leukemia and Lymphoma, 57, 2259 - 2267
A phase I trial to assess the safety, PK and PD of CXD101 in advanced cancer expressing the biomarker HR23B
Eyre TA. et al, (2016), Annals of Oncology, 27
Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin (R) blocking HGF and VEGF, in patients with advanced solid tumors
Middleton MR. et al, (2016), ANNALS OF ONCOLOGY, 27
Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors
Middleton MR. et al, (2016), Annals of Oncology, 27
Loss of Bone Marrow Mesenchymal Stem Cells in Myeloproliferative Neoplasms as an Indicator of Niche Dysregulation
Bishop E. et al, (2016), JOURNAL OF PATHOLOGY, 240, 23 - 23
Restaging oesophageal cancer after neoadjuvant therapy with (18)F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery.
Findlay JM. et al, (2016), Eur Radiol, 26, 3519 - 3533
Cumulative burden of disease: a relevant measure of the late side-effects of cancer treatment.
Aznar MC. et al, (2016), The Lancet. Oncology, 17, 1189 - 1190
EMBRYONIC THYMOPOIESIS IS INITIATED BY AN IMMUNE-RESTRICTED LYMPHO-MYELOID PROGENITOR INDEPENDENTLY OF NOTCH SIGNALING
Luis TC. et al, (2016), EXPERIMENTAL HEMATOLOGY, 44, S65 - S65
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A. et al, (2016), Lancet Oncol, 17, 1283 - 1294
The Experiences of Young Adults With Hodgkin Lymphoma Transitioning to Survivorship: A Grounded Theory Study.
Matheson L. et al, (2016), Oncol Nurs Forum, 43, E195 - E2014
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.
Garbe C. et al, (2016), Eur J Cancer, 63, 201 - 217
Genetic susceptibility to Barrett's oesophagus: Lessons from early studies.
Findlay JM. et al, (2016), United European gastroenterology journal, 4, 485 - 492
Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
Dooley AJ. et al, (2016), Target Oncol, 11, 557 - 563
Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial
Harrington K. et al, (2016), MELANOMA RESEARCH, 26, E4 - E5